REPLIGEN CORP

RGENNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$738.3M

▲ 16.4% YoY

Net Income

$48.9M

▲ 291.6% YoY

EPS

$0.86

▲ 287.0% YoY

Cash

$566.0M

▼ 25.3% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.